These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16189100)

  • 21. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
    Arias CA; Singh KV; Panesso D; Murray BE
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
    Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
    Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
    Ednie L; Shapiro S; Appelbaum PC
    Diagn Microbiol Infect Dis; 2007 May; 58(1):133-6. PubMed ID: 17240107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
    Clark C; Ednie LM; Lin G; Smith K; Kosowska-Shick K; McGhee P; Dewasse B; Beachel L; Caspers P; Gaucher B; Mert G; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1353-61. PubMed ID: 19188385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
    Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
    J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.
    Denis O; Deplano A; Nonhoff C; Hallin M; De Ryck R; Vanhoof R; De Mendonça R; Struelens MJ
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2680-5. PubMed ID: 16870758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.
    Chung M; Antignac A; Kim C; Tomasz A
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2709-17. PubMed ID: 18505853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
    Huang V; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of ceftobiprole against Gram-positive cocci.
    Betriu C; Culebras E; Gómez M; López-Fabal F; Rodríguez-Avial I; Picazo JJ
    Int J Antimicrob Agents; 2010 Aug; 36(2):111-3. PubMed ID: 20554163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Vaudaux P; Gjinovci A; Bento M; Li D; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3789-93. PubMed ID: 16127054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.